Robert Barrow insider trades
Open-market stock purchases and sales by Robert Barrow, Chief Executive Officer at Definium Therapeutics, Inc, from SEC Form 4 filings since Jan 15, 2022.
Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +142%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc | Sold | $1.3M |
| Jun 22, 2026 | DFTX Definium Therapeutics, Inc | Bought (not open market) | — |
| Mar 25, 2026 | DFTX Definium Therapeutics, Inc | Sold | $451K |
| Feb 3, 2026 | DFTX Definium Therapeutics, Inc | Bought (not open market) | — |
| Dec 26, 2025 | MNMD Mind Medicine (MindMed) Inc | Sold | $339K |